TIANSHENG PHARMACEUTICAL GROUP CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.21 CNY | +3.19% |
|
-3.00% | -17.93% |
| 2023 | Tiansheng Pharmaceutical Group Co., Ltd. Announces Executive Appointments | CI |
| 2023 | Tiansheng Pharmaceutical’s Paracetamol Tablet Passes Consistency Test | MT |
Valuation
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|
| Capitalization 1 | 6,477 | 2,722 | 1,708 | 1,507 | 1,660 |
| Enterprise Value (EV) 1 | 6,691 | 3,159 | 2,080 | 1,762 | 1,653 |
| P/E ratio | 23.3 x | 24.5 x | -7.66 x | -3.07 x | -24.5 x |
| Yield | 0.77% | - | - | - | - |
| Capitalization / Revenue | 2.86 x | 1.25 x | 1.02 x | 1.25 x | 2.25 x |
| EV / Revenue | 2.96 x | 1.46 x | 1.24 x | 1.46 x | 2.24 x |
| EV / EBITDA | 17 x | 11.3 x | -19.1 x | -308 x | 68.3 x |
| EV / FCF | -6.79 x | -22.2 x | 16.5 x | 9.44 x | 9.13 x |
| FCF Yield | -14.7% | -4.49% | 6.08% | 10.6% | 11% |
| Price to Book | 2.07 x | 0.85 x | 0.59 x | 0.64 x | 0.73 x |
| Nbr of stocks (in thousands) | 3,18,000 | 3,18,000 | 3,18,000 | 3,18,000 | 3,18,000 |
| Reference price 2 | 20.37 | 8.560 | 5.370 | 4.740 | 5.220 |
| Announcement Date | 23/04/18 | 26/04/19 | 27/04/20 | 26/04/21 | 24/04/22 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|
| Net sales 1 | 2,087 | 2,261 | 2,171 | 1,678 | 1,203 | 736.7 |
| EBITDA 1 | 344.8 | 393.2 | 280.6 | -108.9 | -5.721 | 24.22 |
| EBIT 1 | 274.4 | 303.8 | 178 | -213.8 | -122.6 | -72.44 |
| Operating Margin | 13.15% | 13.43% | 8.2% | -12.74% | -10.19% | -9.83% |
| Earnings before Tax (EBT) 1 | 276.9 | 305.3 | 139.9 | -229.6 | -534.6 | -54.44 |
| Net income 1 | 224.5 | 248.6 | 110.7 | -222.9 | -490.7 | -67.81 |
| Net margin | 10.76% | 10.99% | 5.1% | -13.28% | -40.8% | -9.2% |
| EPS 2 | 0.9400 | 0.8733 | 0.3500 | -0.7008 | -1.543 | -0.2132 |
| Free Cash Flow 1 | 6.343 | -985.9 | -142 | 126.4 | 186.6 | 181.1 |
| FCF margin | 0.3% | -43.6% | -6.54% | 7.53% | 15.51% | 24.59% |
| FCF Conversion (EBITDA) | 1.84% | - | - | - | - | 747.93% |
| FCF Conversion (Net income) | 2.83% | - | - | - | - | - |
| Dividend per Share | - | 0.1573 | - | - | - | - |
| Announcement Date | 02/05/17 | 23/04/18 | 26/04/19 | 27/04/20 | 26/04/21 | 24/04/22 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 308 | 215 | 437 | 372 | 255 | - |
| Net Cash position 1 | - | - | - | - | - | 6.89 |
| Leverage (Debt/EBITDA) | 0.8942 x | 0.5463 x | 1.559 x | -3.413 x | -44.49 x | - |
| Free Cash Flow 1 | 6.34 | -986 | -142 | 126 | 187 | 181 |
| ROE (net income / shareholders' equity) | 13.4% | 10.1% | 3.63% | -7.14% | -18.5% | -3.1% |
| ROA (Net income/ Total Assets) | 5.48% | 4.55% | 2.28% | -2.95% | -1.9% | -1.34% |
| Assets 1 | 4,097 | 5,459 | 4,859 | 7,559 | 25,787 | 5,067 |
| Book Value Per Share 2 | 7.570 | 9.850 | 10.00 | 9.110 | 7.360 | 7.150 |
| Cash Flow per Share 2 | 1.760 | 1.910 | 1.030 | 1.000 | 0.9200 | 1.070 |
| Capex 1 | 426 | 862 | 234 | 93.2 | 92.7 | 114 |
| Capex / Sales | 20.41% | 38.13% | 10.79% | 5.56% | 7.71% | 15.53% |
| Announcement Date | 02/05/17 | 23/04/18 | 26/04/19 | 27/04/20 | 26/04/21 | 24/04/22 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -17.93% | 18Cr | |
| +31.06% | 68TCr | |
| +30.35% | 59TCr | |
| -3.42% | 36TCr | |
| +18.02% | 33TCr | |
| +4.27% | 28TCr | |
| +15.53% | 24TCr | |
| +10.16% | 21TCr | |
| -8.14% | 20TCr | |
| +8.12% | 17TCr |
- Stock Market
- Equities
- 002872 Stock
- Financials Tiansheng Pharmaceutical Group Co., Ltd.